메뉴 건너뛰기




Volumn , Issue , 2012, Pages 91-100

Adaptive design across stages of therapeutic development

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84870915451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139032445.010     Document Type: Chapter
Times cited : (5)

References (42)
  • 1
    • 33646245937 scopus 로고    scopus 로고
    • Adaptive designs in clinical drug development– an executive summary of the phrma working group
    • Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development– An executive summary of the PhRMA working group. J Biopharm Stat 2006; 16: 275–83.
    • (2006) J Biopharm Stat , vol.16 , pp. 275-283
    • Gallo, P.1    Chuang-Stein, C.2    Dragalin, V.3
  • 2
    • 36249017451 scopus 로고    scopus 로고
    • Adaptive designs in clinical drug development: Opportunities, challenges, and scope rel ections following phrma’s november 2006 workshop
    • Krams M, Burman CF, Dragalin V, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope rel ections following PhRMA’s November 2006 workshop. J Biopharm Stat 2007; 17: 957–64.
    • (2007) J Biopharm Stat , vol.17 , pp. 957-964
    • Krams, M.1    Burman, C.F.2    Dragalin, V.3
  • 3
    • 44949171503 scopus 로고    scopus 로고
    • Adaptive design methods in clinical trials–a review
    • Chow SC and Chang M. Adaptive design methods in clinical trials–A review. Orphanet JRare Dis 2008; 3: 11.
    • (2008) Orphanet J , vol.3
    • Chow, S.C.1    Chang, M.2
  • 4
    • 46349091495 scopus 로고    scopus 로고
    • Adaptive clinical trials: Progress and challenges
    • Coffey CS and Kairalla JA. Adaptive clinical trials: Progress and challenges. DrugsRD 2008; 9: 229–42.
    • (2008) Drugs , vol.9 , pp. 229-242
    • Coffey, C.S.1    Kairalla, J.A.2
  • 5
    • 66249141976 scopus 로고    scopus 로고
    • Adaptivity in drug discovery and development
    • Bretz F, Branson M, Burmann CF, et al. Adaptivity in drug discovery and development. Drug Dev Res 2009; 70: 169–90.
    • (2009) Drug Dev Res , vol.70 , pp. 169-190
    • Bretz, F.1    Branson, M.2    Burmann, C.F.3
  • 6
    • 65649093620 scopus 로고    scopus 로고
    • Adaptive designs for confirmatory clinical trials
    • Bretz F, Koenig F, Brannath W, et al. Adaptive designs for confirmatory clinical trials. Stat Med 2009; 28: 1181–1217.
    • (2009) Stat Med , vol.28 , pp. 1181-1217
    • Bretz, F.1    Koenig, F.2    Brannath, W.3
  • 9
    • 46349093564 scopus 로고    scopus 로고
    • A regulatory view on adaptive/flexible clinical trial design
    • Hung HMJ, O’Neill RT, Wang SJ, et al. A regulatory view on adaptive/flexible clinical trial design. Biometrical J 2006; 3: 1–9.
    • (2006) Biometrical , vol.3 , pp. 1-9
    • Hung, H.1    O’Neill, R.T.2    Wang, S.J.3
  • 10
  • 11
    • 33644597596 scopus 로고    scopus 로고
    • The continual reassessment method for dose-finding studies: A tutorial
    • Garrett-Moyer E. The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 2006; 3: 57–71.
    • (2006) Clin Trials , vol.3 , pp. 57-71
    • Garrett-Moyer, E.1
  • 12
    • 54349105104 scopus 로고    scopus 로고
    • Dose finding– a challenge in statistics
    • Bretz F, Hsu J, Pinheiro J, et al. Dose finding– A challenge in statistics. Biometrical J2008; 50: 480–504.
    • (2008) Biometrical J , vol.50 , pp. 480-504
    • Bretz, F.1    Hsu, J.2    Pinheiro, J.3
  • 14
    • 36248961734 scopus 로고    scopus 로고
    • Innovative approaches for designing and analyzing adaptive doseranging trials
    • Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive doseranging trials. J Biopharm Stat 2007; 17: 965–95.
    • (2007) J Biopharm Stat , vol.17 , pp. 965-995
    • Bornkamp, B.1    Bretz, F.2    Dmitrienko, A.3
  • 16
    • 0032989951 scopus 로고    scopus 로고
    • Randomized play-the-winner clinical.Trials: Review and recommendations
    • Rosenberger WF. Randomized play-the-winner clinical.trials: Review and recommendations.Control Clin Trials 1999; 20: 328–42.
    • (1999) Control Clin Trials , vol.20 , pp. 328-342
    • Rosenberger, W.F.1
  • 17
    • 0343088226 scopus 로고
    • Bandit strategies for ethical sequential allocation. Control clin
    • Hardwick JP and Stout QF. Bandit strategies for ethical sequential allocation. Control ClinTrials 1991; 23: 421–24.
    • (1991) Trials , vol.23 , pp. 421-424
    • Hardwick, J.P.1    Stout, Q.F.2
  • 18
    • 77249096450 scopus 로고    scopus 로고
    • The use of minimization in clinical trials
    • Taves DR. The use of minimization in clinical trials. Contemp Clin Trials2010; 31: 180–84.
    • (2010) Contemp Clin Trials , vol.31 , pp. 180-184
    • Taves, D.R.1
  • 19
    • 0028619850 scopus 로고
    • Evaluation of experiments with adaptive interim analyses
    • Bauer P and Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41.
    • (1994) Biometrics , vol.50 , pp. 1029-1041
    • Bauer, P.1    Kohne, K.2
  • 20
    • 0029589385 scopus 로고
    • Designed extension of studies based on conditional power
    • Proschan MA and Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–24.
    • (1995) Biometrics , vol.51 , pp. 1315-1324
    • Proschan, M.A.1    Hunsberger, S.A.2
  • 21
    • 0032732411 scopus 로고    scopus 로고
    • Adaptive sample size calculations in group sequential trials
    • Lehmacher W and Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286–90.
    • (1999) Biometrics , vol.55 , pp. 1286-1290
    • Lehmacher, W.1    Wassmer, G.2
  • 22
    • 0032886394 scopus 로고    scopus 로고
    • Modifications of sample size in group sequential clinical trials
    • Cui L, Hung HMJ and Wang S. Modifications of sample size in group sequential clinical trials. Biometrics1999; 55: 853–57.
    • (1999) Biometrics , vol.55 , pp. 853-857
    • Cui, L.1    Hung, H.2    Wang, S.3
  • 23
    • 0034876356 scopus 로고    scopus 로고
    • Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and classical group sequential approaches
    • Muller HH and Schafer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001; 57: 886–91.
    • (2001) Biometrics , vol.57 , pp. 886-891
    • Muller, H.H.1    Schafer, H.2
  • 24
    • 33748576736 scopus 로고    scopus 로고
    • Adaptive, group sequential, and decision theoretic approaches to sample size determination
    • Mehta CR and Patel NR. Adaptive, group sequential, and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250–69.
    • (2006) Stat Med , vol.25 , pp. 3250-3269
    • Mehta, C.R.1    Patel, N.R.2
  • 25
    • 1842826262 scopus 로고    scopus 로고
    • On the inefficiency of the adaptive design for monitoring clinical trials
    • Tsiatis AA and Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367–78.
    • (2003) Biometrika , vol.90 , pp. 367-378
    • Tsiatis, A.A.1    Mehta, C.2
  • 26
    • 33644770078 scopus 로고    scopus 로고
    • Efficient group sequential designs when there are several eff ect sizes under consideration
    • Jennison C and Turnbull BW. Efficient group sequential designs when there are several eff ect sizes under consideration. Stat Med 2006; 25: 917–32.
    • (2006) Stat Med , vol.25 , pp. 917-932
    • Jennison, C.1    Turnbull, B.W.2
  • 27
    • 0024994537 scopus 로고
    • The role of internal pilot studies in increasing the efficiency of clinical trials
    • Wittes J and Brittain E.The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990; 9: 65–72.
    • (1990) Stat Med , vol.9 , pp. 65-72
    • Wittes, J.1    Brittain, E.2
  • 28
    • 22044443101 scopus 로고    scopus 로고
    • Two-stage sample size re-estimation based on a nuisance parameter: A review
    • Proschan MA. Two-stage sample size re-estimation based on a nuisance parameter: A review. J Biopharm Stat 2005; 15: 559–74.
    • (2005) J Biopharm Stat , vol.15 , pp. 559-574
    • Proschan, M.A.1
  • 29
    • 33748550685 scopus 로고    scopus 로고
    • Sample size recalculation in internal pilot study designs: A review
    • Friede T and Kieser M. Sample size recalculation in internal pilot study designs: A review. Biometrical J 2006; 48: 537–55.
    • (2006) Biometrical J , vol.48 , pp. 537-555
    • Friede, T.1    Kieser, M.2
  • 30
    • 66349091397 scopus 로고    scopus 로고
    • Sample size re-estimation in clinical trials
    • Proschan MA. Sample size re-estimation in clinical trials. Biometrical J 2009; 51: 348–57.
    • (2009) Biometrical J , vol.51 , pp. 348-357
    • Proschan, M.A.1
  • 31
    • 70249116820 scopus 로고    scopus 로고
    • Phase ii trial of coq10 for als find insuffi cient evidence to justify phase iii
    • Kaufman P, Thompson JLP, Levy G, et al. Phase II trial of CoQ10 for ALS find insuffi cient evidence to justify phase III. Ann Neurol 2009; 66: 235–44.
    • (2009) Ann Neurol , vol.66 , pp. 235-244
    • Kaufman, P.1    Thompson, J.2    Levy, G.3
  • 33
    • 0242694372 scopus 로고    scopus 로고
    • Acute stroke therapy by inhibition of neutrophils (Astin): An adaptive dose-response study of uk-279,276 in acute ischemic stroke
    • Krams M, Lees KR, Hacke W, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–48.
    • (2003) Stroke , vol.34 , pp. 2543-2548
    • Krams, M.1    Lees, K.R.2    Hacke, W.3
  • 34
    • 42249087655 scopus 로고    scopus 로고
    • Randomized controlled trial of an oral cgrp receptor antagonist, mk-0974, in acute treatment of migraine
    • Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–12.
    • (2008) Neurology , vol.70 , pp. 1304-1312
    • Ho, T.W.1    Mannix, L.K.2    Fan, X.3
  • 35
    • 52449120660 scopus 로고    scopus 로고
    • Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
    • Whelan HT, Cook JD, Amlie-Lefond CM, et al. Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke 2008; 39: 2627–36.
    • (2008) Stroke , vol.39 , pp. 2627-2636
    • Whelan, H.T.1    Cook, J.D.2    Amlie-Lefond, C.M.3
  • 36
    • 67650492245 scopus 로고    scopus 로고
    • High-dose lovastatin for acute ischemic stroke: Results of the phase i dose escalation neuroprotection with statin therapy for acute recovery trial (neustart)
    • Elkind MSV, Sacco RL, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009; 28: 266–275.
    • (2009) Cerebrovasc , vol.28 , pp. 266-275
    • Elkind, M.1    Sacco, R.L.2    MacArthur, R.B.3
  • 37
    • 77950251479 scopus 로고    scopus 로고
    • Phase iib/iii trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial
    • Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707–711.
    • (2010) Stroke , vol.41 , pp. 707-711
    • Haley, E.C.1    Thompson, J.2    Grotta, J.C.3
  • 38
    • 1542346238 scopus 로고    scopus 로고
    • Calcitonin generelated peptide receptor antagonist bibn 4096 bs for the acute treatment of migraine
    • Olesen J, Diener H, Husstedt IW, et al. Calcitonin generelated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl J Med 2004; 350: 1104–10.
    • (2004) New Engl J Med , vol.350 , pp. 1104-1110
    • Olesen, J.1    Diener, H.2    Husstedt, I.W.3
  • 39
    • 33750893179 scopus 로고    scopus 로고
    • Implementing adaptive designs: Logistical and operational considerations
    • Quinlan JA and Krams M. Implementing adaptive designs: Logistical and operational considerations. Drug Information Journal2006; 40: 437–444.
    • (2006) Drug Information Journal , vol.40 , pp. 437-444
    • Quinlan, J.A.1    Krams, M.2
  • 40
    • 77953666447 scopus 로고    scopus 로고
    • Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development
    • Quinlan J, Gaydos B, Maca J, et al. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010; 7: 167–73.
    • (2010) Clin Trials , vol.7 , pp. 167-173
    • Quinlan, J.1    Gaydos, B.2    Maca, J.3
  • 41
    • 33845891920 scopus 로고    scopus 로고
    • The design of simulation studies in medical statistics
    • Burton A, Altman DG, Royston P, et al. The design of simulation studies in medical statistics. Stat Med 2006; 25: 4279–92.
    • (2006) Stat Med , vol.25 , pp. 4279-4292
    • Burton, A.1    Altman, D.G.2    Royston, P.3
  • 42
    • 70350139975 scopus 로고    scopus 로고
    • Good practices for adaptive clinical trials in pharmaceutical product development
    • Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 2009; 43: 539–56.
    • (2009) Drug Inf J , vol.43 , pp. 539-556
    • Gaydos, B.1    Erson, K.M.2    Berry, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.